🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

15 results for “INTENSITY” Clear

  1. INT230-6

    INTENSITY THERAPEUTICS, INC.

    Sarcoma,Soft Tissue

    phase 3 small molecule active

    1 trial

  2. Trabectedin EVER Pharma 1 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung, Pazopanib PharOS 200 mg film-coated tablets, HALAVEN 0.44 mg/ml solution for injection

    INTENSITY THERAPEUTICS, INC.

    liposarcoma (dedifferentiated, myxoid, round cell or pleomorphic), Leiomyosarcoma (non-uterine), Undifferentiated pleomorphic sarcoma

    phase 3 small molecule active

    1 trial

  3. intensity-modulated radiation therapy

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 3 other active

    1 trial

  4. INT230-6

    INTENSITY THERAPEUTICS, INC.

    Breast Cancer

    phase 2 small molecule active

    2 trials

  5. Intensity-modulated radiation therapy (IMRT) in combination with fluzoparib, abiraterone acetate tablets (II), and prednisone.

    China SXT Pharmaceuticals

    Metastatic Castration-resistant Prostate Cancer

    phase 2 small molecule active

    1 trial

  6. JIN-A02

    INTENSITY THERAPEUTICS, INC.

    EGFR Mutant Advanced Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  7. MPT0B640

    INTENSITY THERAPEUTICS, INC.

    Advanced Solid Tumor

    phase 1 small molecule terminated

    1 trial

  8. MPT0B640

    INTENSITY THERAPEUTICS, INC.

    Covid19

    phase 1 small molecule terminated

    1 trial

  9. Treatment of cancer with Immune Checkpoint Inhibition therapy boosted by High Intensity Focused Ultrasound Histotripsy (the iFOCUS study)

    Disc Medicine

    Metastatic or unresectable solid malignancies. Standard of care treatment options must not be available or not be considered feasible. Patients must have a primary tumor or metastasis that is suitable for HIFU-HT treatment.

    phase 1 other active

    1 trial

  10. Low intensity laser for oral mucositis

    Lxo Ireland Designated Activity Company

    Oral Mucositis

    approved other active

    1 trial

  11. Intensity-modulated radiotherapy

    China SXT Pharmaceuticals

    Nasopharyngeal Carcinoma

    other active

    1 trial

  12. Placebo plus high-intensity statin

    China SXT Pharmaceuticals

    Acute Coronary Syndrome

    small molecule active

    1 trial

  13. Standart medical treatment

    Tarsus Pharmaceuticals

    High Intensity Interval Training

    small molecule active

    1 trial

  14. Surgery combined with Target-reduction intensity-modulated radiotherapy

    China SXT Pharmaceuticals

    Nasopharyngeal Carcinoma

    other active

    1 trial

  15. simultaneous integrated boost intensity-modulated radiation therapy combined with ripretinib

    First Tracks Biotherapeutics

    Gastrointestinal Stromal Tumors

    other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources